Unlike previous signatures that included genes positively associated with TLSs, our signature contains not only genes (ie, CXCL13, CXCL11, CXCL10) with an established role in TLS formation and function, but also genes (ie, TGFB2 and VEGFB) associated with an immunosuppressive tumor microenvironment that may inhibit the development of TLSs.3 The gene discussed is VEGFB; the disease is neoplasm.